25 results on '"Julian, Thomas B"'
Search Results
2. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
- Author
-
Julian, Thomas B., Patel, Nilesh, Dusi, Deborah, Olson, Peter, Nathan, Girija, Jasnosz, Katherine, Isaacs, Gilbert, and Wolmark, Norman
- Subjects
Breast cancer -- Adjuvant treatment ,Lymphatic metastasis -- Diagnosis ,Lymph nodes -- Biopsy ,Health - Published
- 2001
3. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer
- Author
-
Julian, Thomas B., Dusi, Deborah, and Wolmark, Norman
- Subjects
Breast cancer -- Drug therapy ,Lymph nodes -- Medical examination ,Health - Published
- 2002
4. Local failure and acute radiodermatological toxicity in patients undergoing radiation therapy with and without postmastectomy chest wall bolus: Is bolus ever necessary?
- Author
-
Abel, Stephen, Renz, Paul, Trombetta, Mark, Cowher, Michael, Day Werts, E., Julian, Thomas B., and Wegner, Rodney
- Abstract
Purpose Postmastectomy chest wall radiation therapy has historically used bolus to increase dose at the skin surface. Despite the theoretical benefits of bolus, the clinical implications of locoregional tumor control, cosmesis, and the incidence of radiodermatitis are less well characterized. We hypothesized that treatment in the presence or absence of bolus results in equivalent chest wall recurrence rates, but its presence results in more severe acute dermatologic toxicity. Methods and materials Locally advanced breast cancer patients undergoing chest wall radiation therapy were retrospectively reviewed from 2005 to 2015 (n = 106; 53 with bolus, 53 without). Outcomes including local failure, acute skin toxicity, and treatment interruptions were recorded. Median age was 59 years (range, 28-91) and median follow-up was 34 months. Histology was invasive ductal carcinoma (73%), invasive lobular carcinoma (20%), inflammatory (6%), and neuroendocrine (1%). Fifty-nine percent were T3/T4 primary tumors and 29.2% had clinical/pathologic skin involvement. Node-positive patients accounted for 80.2%. Chemotherapy was administered in 84.0%. All patients had 3-dimensional conformal radiation therapy and received a median dose of 61Gy (range, 50-63 Gy). Results Local failure was 6.6% (n = 7) overall, with 4 failures in the bolus group and 3 in the no bolus group. No pathological factors were associated with local failure. Acute grade 2 and 3 skin toxicities (37 vs 22) and treatment interruptions (20 vs 3) were more common in the bolus group ( P < .05). Mean treatment interruption (14.5 vs 5 days) was longer for patients receiving bolus. Patients undergoing treatment interruption were more likely to fail locally than patients not requiring a treatment interruption (17.4% vs 3.6%, P = .0322). Conclusions Bolus omission in adjuvant chest wall radiation therapy may be a reasonable approach to avoid acute skin toxicity and treatment interruptions while preserving local control; however, further study will be needed to reach a definitive conclusion. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Comparison of conservative management techniques in the re-treatment of ipsilateral breast tumor recurrence
- Author
-
Trombetta, Mark, Julian, Thomas B., Werts, E. Day, Colonias, Athanasios, Betler, James, Kotinsley, Katherine, Kim, Yongbok, and Parda, David
- Subjects
- *
CANCER relapse , *RADIOISOTOPE brachytherapy , *BREAST cancer surgery , *CANCER radiotherapy , *BREAST cancer patients , *FEASIBILITY studies , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Purpose: To compare brachytherapy and three-dimensional (3-D) conformal external beam radiotherapy for breast cancer presenting in the previously irradiated breast. Methods and Materials: Thirty-six patients with TIS–T2 breast carcinomas received brachytherapy or 3-D conformal radiotherapy (3-D CRT) after lumpectomy in a previously irradiated breast as an alternative to salvage mastectomy. Brachytherapy consisted of low-dose-rate (LDR) interstitial technique in 21 patients, whereas 11 patients were treated using high-dose-rate (HDR) balloon technique. Four patients received 3-D CRT. Cosmesis was graded according to the Harvard criteria and the Allegheny General Modification of the Harvard criteria. Acute sequelae were graded according to the Common Terminology Criteria for Adverse Events (version 3.0). Results: Thirty-five of 36 patients remained free of local failure, with a mean followup of 37 months. Five patients treated with LDR developed Grade II and two developed Grade III acute side effects. No patient treated with balloon brachytherapy or 3-D CRT developed a Grade II or higher acute effect. Cosmetically, 12 LDR interstitial patients were scored as Grade I, six as Grade II, and three as Grade III. Nine of the HDR patients were scored as Grade I, one as Grade II, and one as Grade III. Two 3-D CRT patients were scored as Grade II and two as Grade III. The Allegheny Modification of the Harvard criteria more accurately reflected the cosmetic effects of re-treatment. Conclusion: Brachytherapy is feasible for patients who desire breast preservation in a previously irradiated breast. All techniques demonstrated similar local control rates. Acute side effects were less, and cosmesis was superior in HDR balloon brachytherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
6. Reduction in Radiation-Induced Morbidity by Use of an Intercurrent Boost in the Management of Early-Stage Breast Cancer
- Author
-
Trombetta, Mark, Julian, Thomas B., Valakh, Vladimir, Greenberg, Larisa, Labban, George, Khalid, Mian K., Werts, E. Day, and Parda, David
- Subjects
- *
BREAST cancer research , *CANCER radiotherapy complications , *SKIN inflammation , *TREATMENT effectiveness , *ELECTRONS , *MEDICAL statistics - Abstract
Purpose: Electron or photon boost immediately following whole-breast irradiation performed after conservation surgery for early-stage breast cancer is the accepted standard of care. This regimen frequently results in Grade III dermatitis, causing discomfort or treatment interruption. Herein, we compare patients treated with whole-breast irradiation followed by boost compared with a cohort with a planned intercurrent radiation boost. Methods and Materials: The records of 650 consecutive breast cancer patients treated at Allegheny General Hospital (AGH) between 2000 and 2008 were reviewed. Selected for this study were 327 patients with T1 or T2 tumors treated with external beam radiotherapy postlumpectomy. One hundred and sixty-nine patients were treated by whole-breast radiotherapy (WBRT) followed by boost at completion. One hundred fifty-eight were treated with a planned intercurrent boost (delivered following 3,600 cGy WBRT). The mean whole breast radiation dose in the conventionally treated group was 5,032 cGy (range, 4500–5400 cGy), and the mean whole breast dose was 5,097 cGy (range, 4860–5040 cGy) in the group treated with a planned intercurrent boost. Results: The occurrence of Grade III dermatitis was significantly reduced in the WBRT/intercurrent boost group compared with the WBRT/boost group (0.6% vs. 8.9%), as was the incidence of treatment interruption (1.9% vs. 14.2%). With a median follow-up of 32 months and 27 months, respectively, no significant difference in local control was identified. Conclusions: Patients treated with intercurrent boost developed less Grade III dermatitis and unplanned treatment interruptions with similar local control. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
7. Ductal Carcinoma In Situ: Biology, Diagnosis, and New Therapies.
- Author
-
Valenzuela, Marcia and Julian, Thomas B.
- Subjects
MAMMOGRAMS ,BREAST cancer patients ,TRASTUZUMAB ,TUMOR growth ,MAGNETIC resonance imaging ,RADIOTHERAPY ,THERAPEUTICS - Abstract
The incidence of ductal carcinoma in situ (DCIS) has markedly increased as a result of the use of screening mammography. Whether DCIS is a premalignant lesion or a cancer remains a cause of debate, but evidence supports the idea that DCIS evolves into invasive breast cancer based on histologic patterns, similar risk factors, and genetic similarities. Microcalcifications identified during mammography generally raise the suspicion of DCIS, and biopsy, often by core needle, confirms such a diagnosis. The extent of disease can be further delineated by breast magnetic resonance imaging. Radiation therapy in breast-conserving treatment, along with tamoxifen, decreases the overall rate of local recurrence in patients with DCIS. Studies in the treatment of DCIS exploring partial breast radiation and trastuzumab are under way. Ongoing investigations with comparative genomic hybridization suggest that there are independent, evolutionary genetic pathways within DCIS. Genome-wide microarray-based gene expression analyses are now providing new opportunities to discover genes that are specifically activated or inactivated during the course of breast cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
8. Boost Radiotherapy for the Treatment of Ductal Carcinoma In Situ Remains Controversial.
- Author
-
Tower, Amelia, Duggal, Shivani, and Julian, Thomas B.
- Published
- 2015
- Full Text
- View/download PDF
9. Are Margins Bigger Than “No Ink on Tumor” Better? Decidedly Not!
- Author
-
Venditti, Charis A., Duggal, Shivani S., and Julian, Thomas B.
- Published
- 2014
- Full Text
- View/download PDF
10. Long-term followup of breast preservation by re-excision and balloon brachytherapy after ipsilateral breast tumor recurrence.
- Author
-
Trombetta, Mark, Hall, Michael, and Julian, Thomas B.
- Subjects
- *
BREAST tumor treatment , *PRESERVATION of organs, tissues, etc. , *RADIOISOTOPE brachytherapy , *BREAST surgery , *HODGKIN'S disease , *FOLLOW-up studies (Medicine) , *CANCER relapse - Abstract
Purpose: To report our long-term experience with balloon brachytherapy in retreatment of the breast after ipsilateral breast tumor recurrence. Methods and Materials: Between March 2004 and June 2012, 18 patients previously treated with external beam radiotherapy were retreated using either the MammoSite (Hologic Corporation, Marlborough, MA), MammoSite ML (Hologic Corporation), or the Contura (Bard Peripheral Vascular, Inc., Tempe, AZ) brachytherapy devices. Sixteen patients were treated for an ipsilateral breast tumor recurrence after breast conservation surgery and postoperative irradiation (11 with infiltrating ductal carcinoma [IDC] and 6 with ductal carcinoma in situ [DCIS]), whereas 2 patients developed an in-field breast cancer likely associated with Hodgkin disease mantle irradiation (27 and 17 years prior, respectively). The recurrent histology of seven was IDC, with seven others recurring as DCIS, three as a combination of IDC/DCIS, and one as infiltrating lobular carcinoma. All patients received a twice-daily tumor dose of 3400 cGy at 340 cGy per fraction. Acute and chronic side effects were graded by the Common Terminology Criteria for Adverse Events, version 4.0. Cosmesis was graded by both the Harvard Cosmesis Scale and the Allegheny General Modification of the Harvard Scale. Results: With a mean of followup of 39.6 months, only 2 patients developed a local recurrence. One patient developed an inflammatory recurrence from what was identified as a moderately differentiated T1N0M0 estrogen receptor-positive recurrence, and the second developed a recurrence immediately adjacent to the implant site. Both patients were treated locally by salvage mastectomy. The patient who developed an inflammatory recurrence rapidly developed visceral metastases including brain lesions and succumbed to her progressive disease. The second patient was successfully salvaged with uncomplicated mastectomy, and she survives to this date. One patient developed a chronic abscess in the sinus tract of the balloon, which required mastectomy, and one developed a post-treatment infection in the catheter tract, which was successfully treated with oral antibiotics. Cosmesis as graded by the Harvard cosmesis criteria and the Allegheny General Modification Score diminished one grade in only 2 patients. All other patients had stable cosmetic scores. Conclusions: Use of balloon brachytherapy devices in the treatment of the previously irradiated breast is feasible and may provide adequate local control and acceptable cosmesis in carefully selected patients. Further study and refinement of this therapy is required for more definitive results. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
- Author
-
Krag, David N, Anderson, Stewart J, Julian, Thomas B, Brown, Ann M, Harlow, Seth P, Costantino, Joseph P, Ashikaga, Takamaru, Weaver, Donald L, Mamounas, Eleftherios P, Jalovec, Lynne M, Frazier, Thomas G, Noyes, R Dirk, Robidoux, André, Scarth, Hugh MC, and Wolmark, Norman
- Subjects
- *
SENTINEL lymph nodes , *LYMPH nodes , *SURGERY , *COMPARATIVE studies , *BREAST cancer , *HEALTH outcome assessment , *ONCOLOGIC surgery , *RANDOMIZED controlled trials - Abstract
Summary: Background: Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND). The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether SLN resection in patients with breast cancer achieves the same survival and regional control as ALND, but with fewer side-effects. Methods: NSABP B-32 was a randomised controlled phase 3 trial done at 80 centres in Canada and the USA between May 1, 1999, and Feb 29, 2004. Women with invasive breast cancer were randomly assigned to either SLN resection plus ALND (group 1) or to SLN resection alone with ALND only if the SLNs were positive (group 2). Random assignment was done at the NSABP Biostatistical Center (Pittsburgh, PA, USA) with a biased coin minimisation approach in an allocation ratio of 1:1. Stratification variables were age at entry (≤49 years, ≥50 years), clinical tumour size (≤2·0 cm, 2·1–4·0 cm, ≥4·1 cm), and surgical plan (lumpectomy, mastectomy). SLN resection was done with a blue dye and radioactive tracer. Outcome analyses were done in patients who were assessed as having pathologically negative sentinel nodes and for whom follow-up data were available. The primary endpoint was overall survival. Analyses were done on an intention-to-treat basis. All deaths, irrespective of cause, were included. The mean time on study for the SLN-negative patients with follow-up information was 95·6 months (range 70·1–126·7). This study is registered with ClinicalTrials.gov, number NCT00003830. Findings: 5611 women were randomly assigned to the treatment groups, 3989 had pathologically negative SLN. 309 deaths were reported in the 3986 SLN-negative patients with follow-up information: 140 of 1975 patients in group 1 and 169 of 2011 in group 2. Log-rank comparison of overall survival in groups 1 and 2 yielded an unadjusted hazard ratio (HR) of 1·20 (95% CI 0·96–1·50; p=0·12). 8-year Kaplan-Meier estimates for overall survival were 91·8% (95% CI 90·4–93·3) in group 1 and 90·3% (88·8–91·8) in group 2. Treatment comparisons for disease-free survival yielded an unadjusted HR of 1·05 (95% CI 0·90–1·22; p=0·54). 8-year Kaplan-Meier estimates for disease-free survival were 82·4% (80·5–84·4) in group 1 and 81·5% (79·6–83·4) in group 2. There were eight regional-node recurrences as first events in group 1 and 14 in group 2 (p=0·22). Patients are continuing follow-up for longer-term assessment of survival and regional control. The most common adverse events were allergic reactions, mostly related to the administration of the blue dye. Interpretation: Overall survival, disease-free survival, and regional control were statistically equivalent between groups. When the SLN is negative, SLN surgery alone with no further ALND is an appropriate, safe, and effective therapy for breast cancer patients with clinically negative lymph nodes. Funding: US Public Health Service, National Cancer Institute, and Department of Health and Human Services. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
12. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
- Author
-
Krag, David N, Anderson, Stewart J, Julian, Thomas B, Brown, Ann M, Harlow, Seth P, Ashikaga, Takamaru, Weaver, Donald L, Miller, Barbara J, Jalovec, Lynne M, Frazier, Thomas G, Noyes, R Dirk, Robidoux, André, Scarth, Hugh MC, Mammolito, Denise M, McCready, David R, Mamounas, Eleftherios P, Costantino, Joseph P, and Wolmark, Norman
- Subjects
- *
LYMPH nodes , *BREAST cancer , *CLINICAL trials , *SURGICAL excision , *SURGICAL complications , *CANCER invasiveness - Abstract
Summary: Background: The goals of axillary-lymph-node dissection (ALND) are to maximise survival, provide regional control, and stage the patient. However, this technique has substantial side-effects. The purpose of the B-32 trial is to establish whether sentinel-lymph-node (SLN) resection can achieve the same therapeutic goals as conventional ALND but with decreased side-effects. The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone. Methods: 5611 women with invasive breast cancer were randomly assigned to receive either SLN resection followed by immediate conventional ALND (n=2807; group 1) or SLN resection without ALND if SLNs were negative on intraoperative cytology and histological examination (n=2804; group 2) in the B-32 trial. Patients in group 2 underwent ALND if no SLNs were identified or if one or more SLNs were positive on intraoperative cytology or subsequent histological examination. Primary endpoints, including survival, regional control, and morbidity, will be reported later. Secondary endpoints are accuracy and technical success and are reported here. This trial is registered with the Clinical Trial registry, number NCT00003830. Findings: Data for technical success were available for 5536 of 5611 patients; 75 declined protocol treatment, had no SLNs removed, or had no SLN resection done. SLNs were successfully removed in 97·2% of patients (5379 of 5536) in both groups combined. Identification of a preincision hot spot was associated with greater SLN removal (98·9% [5072 of 5128]). Only 1·4% (189 of 13171) of SLN specimens were outside of axillary levels I and II. 65·1% (8571 of 13 171) of SLN specimens were both radioactive and blue; a small percentage was identified by palpation only (3·9% [515 of 13 171]). The overall accuracy of SLN resection in patients in group 1 was 97·1% (2544 of 2619; 95% CI 96·4–97·7), with a false-negative rate of 9·8% (75 of 766; 95% CI 7·8–12·2). Differences in tumour location, type of biopsy, and number of SLNs removed significantly affected the false-negative rate. Allergic reactions related to blue dye occurred in 0·7% (37 of 5588) of patients with data on toxic effects. Interpretation: The findings reported here indicate excellent balance in clinical patient characteristics between the two randomised groups and that the success of SLN resection was high. These findings are important because the B-32 trial is the only trial of sufficient size to provide definitive information related to the primary outcome measures of survival and regional control. Removal of more than one SLN and avoidance of excisional biopsy are important variables in reducing the false-negative rate. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
13. Mammary fat necrosis following radiotherapy in the conservative management of localized breast cancer: Does it matter?
- Author
-
Trombetta, Mark, Valakh, Vladimir, Julian, Thomas B., Werts, E. Day, and Parda, David
- Subjects
- *
FAT necrosis , *MAMMARY glands , *MAMMOGRAMS , *BREAST cancer magnetic resonance imaging , *CANCER radiotherapy complications , *LUMPECTOMY , *BREAST ultrasound , *NEEDLE biopsy of the breast - Abstract
Abstract: Purpose: Fat necrosis is a well-described and relatively common complication arising from post-lumpectomy irradiation of the breast, most commonly breast brachytherapy. We wish to assess the clinical significance of fat necrosis resulting from post-lumpectomy breast irradiation. Methods: We reviewed the literature to determine the overall incidence and significance of fat necrosis to determine whether or not fat necrosis poses a significant clinical problem. Results: Fat necrosis occurs in up to one-quarter of patients following post-lumpectomy breast irradiation. Only rarely is invasive intervention required however, it does significantly degrade the quality of all modalities of breast imaging. Conclusions: Fat necrosis is a common complication of radiotherapy which rarely requires therapeutic intervention. However, post-therapeutic clinical imaging such as mammography, ultrasound and magnetic resonance imaging are affected which may result in additional diagnostic procedures up to and including biopsy. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
14. Short-Term Follow-Up Mammography in Breast Conservation Therapy Likely Leads to Unnecessary Downstream Workup: A Longitudinal Study.
- Author
-
Hasan, Shaakir, Abel, Stephen, Simpson-Camp, LaShondria, Witten, Meredith, Aguilera, Luis, Teng, Leslie, Philp, Frances Hite, Julian, Thomas B., Trombetta, Mark, Karlovits, Stephen, and Cowher, Michael
- Subjects
- *
MAMMOGRAMS , *BREAST , *HUMAN anatomy , *MAMMARY glands , *CONSERVATION & restoration , *BREAST tumors , *LONGITUDINAL method , *TIME , *LUMPECTOMY , *RETROSPECTIVE studies - Abstract
Purpose: To analyze the effect of post-radiation therapy (XRT) mammographic timing and radiation technique in relation to additional downstream workup for 569 breast conservation therapy patients treated with adjuvant XRT after their initial surveillance mammogram (MMG).Methods and Materials: From January 2011 to December 2014, 569 breast cancer patients treated with breast conservation surgery and adjuvant XRT with a follow-up MMG were reviewed. Patients were stratified by the time interval until their first post-XRT MMG, and by XRT technique-whole breast (472), accelerated partial breast (96), conventional fractionation (373), hypofractionation (94), surgical cavity boosts (407), or no boost (66). The primary endpoint was further imaging after the initial MMG.Results: Additional workup for those receiving an MMG within 3 months of completing XRT was 51% (73 of 143), compared with 40% (84 of 210) with MMG between 3 and 6 months and 34.5% (75 of 216) with MMG after 6 months (P=.04). Radiation boost to the postoperative bed was associated with further downstream imaging, whereas accelerated partial-breast irradiation and hypofractionated treatment were not.Conclusions: Breast conservation therapy patients who underwent screening MMG before 6 months after completion of XRT were more likely to undergo downstream workup, including additional biopsies. Accelerated and hypofractionated radiation techniques were not associated with supplementary workup. Further study is needed to assess appropriate selection of high-risk patients and possible negative implications of earlier post-XRT screening MMG. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Contura Multi-Lumen Balloon Breast Brachytherapy Catheter: Comparative Dosimetric Findings of a Phase 4 Trial
- Author
-
Arthur, Douglas W., Vicini, Frank A., Todor, Dorin A., Julian, Thomas B., Cuttino, Laurie W., and Mukhopadhyay, Nitai D.
- Subjects
- *
BREAST cancer , *CANCER radiotherapy , *RADIATION dosimetry , *CATHETERS , *STATISTICAL significance , *MEDICAL statistics - Abstract
Purpose: Final dosimetric findings of a completed, multi-institutional phase 4 registry trial using the Contura Multi-Lumen Balloon (MLB) breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI) in patients with early-stage breast cancer are presented. Methods and Materials: Three dosimetric plans with identical target coverage were generated for each patient for comparison: multilumen multidwell (MLMD); central-lumen multidwell (CLMD); and central-lumen single-dwell (CLSD) loading of the Contura catheter. For this study, a successful treatment plan achieved ideal dosimetric goals and included the following: ≥95% of the prescribed dose (PD) covering ≥95% of the target volume (TV); maximum skin dose ≤125% of the PD; maximum rib dose ≤145% of the PD; and V150 ≤50 cc and V200 ≤10 cc. Results: Between January 2008 and February 2011, 23 institutions participated. A total of 318 patients were available for dosimetric review. Using the Contura MLB, all dosimetric criteria were met in 78.93% of cases planned with MLMD versus 55.38% with the CLMD versus 37.66% with the CLSD (P≤.0001). Evaluating all patients with the full range of skin to balloon distance represented, median maximum skin dose was reduced by 12% and median maximum rib dose by 13.9% when using MLMD-based dosimetric plans compared to CLSD. The dosimetric benefit of MLMD was further demonstrated in the subgroup of patients where skin thickness was <5 mm, where MLMD use allowed a 38% reduction in median maximum skin dose over CLSD. For patients with rib distance <5 mm, the median maximum rib dose reduction was 27%. Conclusions: Use of the Contura MLB catheter produced statistically significant improvements in dosimetric capabilities between CLSD and CLMD treatments. This device approach demonstrates the ability not only to overcome the barriers of limited skin thickness and close rib proximity, but to consistently achieve a higher standard of dosimetric planning goals. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
16. Optimal application of the Contura multilumen balloon breast brachytherapy catheter vacuum port to deliver accelerated partial breast irradiation
- Author
-
Tokita, Kenneth M., Cuttino, Laurie W., Vicini, Frank A., Arthur, Douglas W., Todor, Dorin A., Julian, Thomas B., and Lyden, Maureen R.
- Subjects
- *
RADIOISOTOPE brachytherapy , *IRRADIATION , *CATHETERIZATION , *MAMMOGRAMS , *DOSE-response relationship in ionizing radiation - Abstract
Purpose: The impact of using the Contura multilumen balloon (MLB) (SenoRx, Inc., Irvine, CA) breast brachytherapy catheter’s vacuum port in patients treated with accelerated partial breast irradiation (APBI) was analyzed. Methods and Materials: Data from 32 patients at two sites were reviewed. Variables analyzed included the seroma fluid (SF):air volume around the MLB before and after vacuum port use and on its ability to improve (1) the eligibility of patients for APBI and (2) dose coverage of the planning target volume for evaluation (PTV_EVAL) in eligible patients. Results: The median SF/air volume before vacuum removal was 6.8cc vs. 0.8cc after vacuum removal (median reduction in SF/air volume was 90.5%). Before vacuum port use, the median SF/air volume expressed as percentage of the PTV_EVAL was 7.8% (range, 1.9–26.6) in all patients. After application of the vacuum, this was reduced to 1.2%. Before vacuum port use, 10 (31.3%) patients were not considered acceptable candidates for APBI because the SF/air volume:PTV_EVAL ratio (SF:PTV) was greater than 10% (range, 10.1–26.6%; median, 15.2%). After vacuum port use, the median SF:PTV ratio was 1.6% for a median reduction of 91.5%. In addition, the percentage of the prescribed dose covering greater than or equal to 90% of the PTV_EVAL proportionally increased a median of 8% (range, 3–10%) in eligible patients. Conclusion: Use of the Contura MLB vacuum port significantly improved the conformity of the target tissue to the balloon surface, leading to reproducible dose delivery and increased target volume coverage. In addition, application of the vacuum allowed the safe treatment of unacceptable patients with APBI. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Improvements in Critical Dosimetric Endpoints Using the Contura Multilumen Balloon Breast Brachytherapy Catheter to Deliver Accelerated Partial Breast Irradiation: Preliminary Dosimetric Findings of a Phase IV Trial
- Author
-
Arthur, Douglas W., Vicini, Frank A., Todor, Dorin A., Julian, Thomas B., and Lyden, Maureen R.
- Subjects
- *
RADIATION dosimetry , *RADIOISOTOPE brachytherapy , *CATHETERS , *IRRADIATION , *BREAST diseases , *SKIN abnormalities , *MEDICAL statistics , *CANCER tomography - Abstract
Purpose: Dosimetric findings in patients treated with the Contura multilumen balloon (MLB) breast brachytherapy catheter to deliver accelerated partial breast irradiation (APBI) on a multi-institutional Phase IV registry trial are presented. Methods and Materials: Computed tomography–based three-dimensional planning with dose optimization was performed. For the trial, new ideal dosimetric goals included (1) ≥95% of the prescribed dose (PD) covering ≥90% of the target volume, (2) a maximum skin dose ≤125% of the PD, (3) maximum rib dose ≤145% of the PD, and (4) the V150 ≤50 cc and V200 ≤10 cc. The ability to concurrently achieve these dosimetric goals using the Contura MLB was analyzed. Results: 144 cases were available for review. Using the MLB, all dosimetric criteria were met in 76% of cases. Evaluating dosimetric criteria individually, 92% and 89% of cases met skin and rib dose criteria, respectively. In 93% of cases, ideal target volume coverage goals were met, and in 99%, dose homogeneity criteria (V150 and V200) were satisfied. When skin thickness was ≥5 mm to <7 mm, the median skin dose was limited to 120.1% of the PD, and when skin thickness was <5 mm, the median skin dose was 124.2%. When rib distance was <5 mm, median rib dose was reduced to 136.5% of the PD. When skin thickness was <7 mm and distance to rib was <5 mm, median skin and rib doses were jointly limited to 120.6% and 142.1% of the PD, respectively. Conclusion: The Contura MLB catheter provided the means of achieving the imposed higher standard of dosimetric goals in the majority of clinical scenarios encountered. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
18. Accelerated Partial Breast Irradiation Consensus Statement from the American Society for Radiation Oncology (ASTRO)
- Author
-
Smith, Benjamin D., Arthur, Douglas W., Buchholz, Thomas A., Haffty, Bruce G., Hahn, Carol A., Hardenbergh, Patricia H., Julian, Thomas B., Marks, Lawrence B., Todor, Dorin A., Vicini, Frank A., Whelan, Timothy J., White, Julia, Wo, Jennifer Y., and Harris, Jay R.
- Published
- 2009
- Full Text
- View/download PDF
19. Image-Detected Breast Cancer: State of the Art Diagnosis and Treatment
- Author
-
Silverstein, Melvin J., Lagios, Michael D., Recht, Abram, Allred, D. Craig, Harms, Steven E., Holland, Roland, Holmes, Dennis R., Hughes, Lorie L., Jackman, Roger J., Julian, Thomas B., Kuerer, Henry M., Mabry, Helen C., McCready, David R., McMasters, Kelly M., Page, David L., Parker, Steve H., Pass, Helen A., Pegram, Mark, Rubin, Eva, and Stavros, A. Thomas
- Published
- 2005
- Full Text
- View/download PDF
20. Accelerated Partial-Breast Irradiation: Trial by Media or by Science?
- Author
-
Cuttino, Laurie W., White, Julia R., Rabinovitch, Rachel, Gewirtz, David A., Anscher, Mitchell S., Wazer, David E., Vicini, Frank A., Julian, Thomas B., and Arthur, Douglas W.
- Published
- 2012
- Full Text
- View/download PDF
21. In Reply to Dr. Beal et al
- Author
-
Smith, Benjamin D., Arthur, Douglas W., Todor, Dorin A., Buchholz, Thomas A., Haffty, Bruce G., Hahn, Carol A., Hardenbergh, Patricia H., Julian, Thomas B., Marks, Lawrence B., Vicini, Frank A., Whelan, Timothy J., White, Julia, Wo, Jennifer Y., and Harris, Jay R.
- Published
- 2010
- Full Text
- View/download PDF
22. Initial dosimetric experience: Contura™ Multilumen Balloon Registry Trial
- Author
-
Arthur, Douglas W., Todor, Dorin, Vicini, Frank A., and Julian, Thomas B.
- Published
- 2009
- Full Text
- View/download PDF
23. Long-Term Followup of Intracavitary Balloon Catheter Retreatment Irradiation of the Breast
- Author
-
Trombetta, Mark G., Erb, Kathleen, Hall, Michael, and Julian, Thomas B.
- Published
- 2013
- Full Text
- View/download PDF
24. Response to “Unacceptable Cosmesis in a Protocol Investigating Intensity-Modulated Radiotherapy With Active Breathing Control for Accelerated Partial-Breast Irradiation” (Int J Radiat Oncol Biol Phys 2010;76:71–78) and “Toxicity of Three-Dimensional Conformal Radiotherapy for Accelerated Partial Breast Irradiation”Int J Radiat Oncol Biol Phys 2009;75:1290–1296)
- Author
-
Wolmark, Norman, Curran, Walter J., Vicini, Frank, White, Julia, Costantino, Joseph P., Arthur, Douglas, Kuske, Robert, Rabinovitch, Rachel, Julian, Thomas B., and Parda, David S.
- Published
- 2010
- Full Text
- View/download PDF
25. Consistent Reductions in Skin Doses Using the Contura™ Multi-Lumen Balloon Breast Brachytherapy Catheter to Deliver Accelerated Partial Breast Irradiation
- Author
-
Prestidge, Bradley R., Vicini, Frank A., Arthur, Douglas W., Todor, Dorin A., Julian, Thomas B., and Lyden, Maureen R.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.